Key Takeaways
- A DSO affiliation is a complex transaction where the selling dentist acts as seller, partner, and investor. Owners benefit from understanding all three roles before signing.
- DSO deals commonly deliver 60–85%+ of total consideration as cash at close, with the balance in rollover equity and earnouts, and usually require at least a 5-year post-close employment commitment.
- Valuation in DSO transactions is based on normalized EBITDA multiples (often 6x–12x in 2026), which can produce very different results than traditional private-buyer percentage-of-collections pricing.
- Key risks can include loss of clinical autonomy, restrictive covenants, equity risk from weaker DSOs, and a gap between headline price and actual cash received at closing.
- McLerran & Associates provides dental-only, sell-side advisory services and runs both DSO/private-equity and doctor-to-doctor private-buyer paths to create side-by-side valuations for practice owners.
Talk with McLerran & Associates about your practice and goals.
Why the DSO Path Exists and How the Market Shifted
For most of dental history, practice transitions followed a simple pattern. A dentist sold to another dentist, often through a local broker, in a deal priced as a percentage of annual collections. That model still exists and still works well for many practices. Over roughly the last decade, however, private-equity-backed Dental Service Organizations reshaped the landscape, poured capital into the space after COVID, and created a second pathway that can be more lucrative for larger practices.
The scale of that shift is measurable. ADA Health Policy Institute data show that private-practice dentist ownership declined from 84.7% in 2005 to 72.5% in 2023, and approximately 16% of all U.S. dentists are DSO-affiliated, rising to 27% among dentists less than 10 years out of dental school, per ADA Health Policy Institute data (which may slightly undercount DSO affiliation). Dental was the busiest healthcare M&A category in 2024, with at least 161 private-equity-backed transactions, up 10.3% from 2023.
This activity created opportunity and widened a critical information gap. A practice owner sells once in a lifetime. A DSO negotiates acquisitions every week. The result is a profoundly uneven table. An unrepresented dentist negotiating directly with a single DSO faces a counterparty that understands enterprise valuation, sees dozens of deals, and benefits from the lack of competition for the practice.
The Real Pros of Selling a Dental Practice to a DSO Explained as Mechanisms
That information gap cuts both ways. DSO deals also offer real advantages, and each one operates through a specific mechanism that affects how much value the owner actually receives.
Administrative relief. DSOs provide compliance management, HR, payroll, IT, supply procurement, and billing infrastructure. For an owner who has spent years managing staff problems and operational fires, this relief can be substantial. It usually begins on day one after closing.
Capital access and growth support. A DSO affiliation can fund expansion such as additional operatories, new locations, or equipment upgrades using the platform’s capital rather than the owner’s personal debt. For a practice at an inflection point, this support can accelerate growth that would otherwise take years to self-finance.
Liquidity and taking chips off the table. A DSO deal allows an owner to convert a large, illiquid asset into cash while continuing to practice. For owners who have built significant wealth inside a single business, this diversification can be meaningful from a personal financial-planning standpoint.
Rollover equity and the “second bite.” Most DSO deals include a rollover equity component, meaning an ownership stake in the DSO platform that the seller retains rather than converting to cash. This is often described as a “second bite of the apple” if the platform later sells at a higher valuation. That upside can be real, but it requires treating the equity as an investment. Up to roughly 40% of a DSO deal can be paid in equity rather than cash, so the owner effectively buys stock in the DSO and benefits from underwriting it with the same rigor as any investment decision.
The structure of that equity matters significantly. JV-level equity, meaning ownership in a joint venture at the practice or regional level, typically carries distributions, which provide a higher income floor but a lower ceiling on upside. Holding-company equity, meaning ownership in the DSO’s parent entity, typically carries no distributions, but its higher ceiling can multiply several times over at a platform-level exit. Sellers who enter a process without understanding these structure distinctions can be at a significant disadvantage in evaluating competing offers even when headline multiples appear similar.
Much of the cash received in a DSO deal may be treated at long-term capital gains rates rather than ordinary income, which can affect after-tax proceeds. Tax advisors can model the specific treatment for a given transaction structure.
The Real Cons of Selling a Dental Practice to a DSO Explained as Terms
The downsides of a DSO affiliation usually appear as specific deal terms in the letter of intent and the asset purchase agreement.
Work-back mandates. On a DSO deal, a minimum 5-year working agreement is typical, though a shorter work-back may be possible if the dentist has already worked mostly out of the chair, compared with the 4-to-8-week transition common in a private doctor-to-doctor sale. Buyers now require a minimum 5-year post-close employment term more consistently. A shorter work-back may be negotiable when the owner already functions mainly as a CEO rather than a full-time producer.
Loss of clinical and operational autonomy. DSO management services agreements typically run 20 to 40 years and are difficult to unwind. A DSO sale therefore creates a multi-decade operating relationship. The degree of clinical autonomy preserved after closing varies significantly by DSO and by how the management services agreement is drafted.
Non-compete and non-solicitation obligations. DSO transactions almost always include restrictive covenants. Restrictive covenants in dental transactions should be analyzed under the laws of each applicable jurisdiction rather than assumed enforceable, because state law varies considerably. Courts are generally more willing to enforce non-competes in practice-sale contexts than in employment contexts, since the buyer has paid for the practice’s goodwill.
The gap between headline price and cash received. The headline number in a DSO offer often differs from cash at close. Cash at closing in a DSO deal can be materially lower than the headline value when consideration includes rollover equity, a seller note, an earnout, an escrow, a holdback, or a working-capital true-up.
The risk of a poorly backed DSO. Several DSO platforms carrying high debt loads against their EBITDA have filed for bankruptcy or undergone debt restructuring since 2022, and common equity holders in those situations typically recover little or nothing. Partnering with an undercapitalized or poorly run DSO can put a meaningful share of the owner’s total proceeds at risk.
How to Read the DSO Offer: Cash at Close, Rollover Equity, and Earnouts
A DSO offer has three main components, and each one behaves differently over time and after tax.
Cash at close is the only guaranteed portion of the deal. DSO offers are commonly structured with 60% to 85% or more of total consideration paid as cash at close, though the range varies by deal size, structure, and buyer. This portion is taxable in the year of closing, and the allocation across asset classes such as equipment, covenants not to compete, and goodwill affects the tax treatment of each dollar received.
Rollover equity is the ownership stake retained in the DSO platform. It is illiquid until the platform achieves a liquidity event, typically a secondary private-equity buyout, a recapitalization, or a strategic sale. Secondary private-equity buyouts typically occur 4 to 7 years after the initial affiliation, with recapitalizations often in the 3-to-5-year range and strategic sales or IPOs sometimes 5 to 10+ years out. The gain on rollover equity at that liquidity event is generally treated at long-term capital gains rates if held more than 12 months. Tax advisors can confirm the specific treatment for a given structure.
Earnouts are contingent payments tied to post-close performance, typically EBITDA or production targets over a defined period. Earnout or retention payments in DSO deals typically represent 15% to 30% of deal value, paid over the post-closing employment period, and are contingent on meeting specified performance targets. Non-punitive earnout structures, such as pro-rata provisions that pay most of the earnout even on a near-miss of an EBITDA target, can be a meaningful negotiation point that significantly affects total proceeds.
Because each of these three components behaves differently over time, comparing a DSO offer against a private-buyer offer or against simply keeping the practice and taking distributions benefits from modeling each path across multiple time horizons such as 3, 5, 7, and 10 years. Conservative assumptions about when and at what multiple the DSO platform might recapitalize help make offers genuinely comparable rather than superficially similar.
Valuation: How DSO Deals Are Priced vs. Private-Buyer Deals
DSO and private-equity deals are priced on a multiple of EBITDA, meaning the practice’s operating earnings after normalizing owner compensation to a market-rate clinical wage and adding back personal, discretionary, and non-recurring expenses. Doctor-to-doctor private deals are typically priced on a percentage of annual collections or a multiple of seller’s discretionary earnings (SDE), which is a broader measure of owner benefit that includes the owner’s compensation.
The two methods can produce very different numbers for the same practice. A side-by-side valuation across both markets can be especially useful for owners in the middle of the revenue range.
EBITDA multiples in DSO transactions vary by practice size, number of doctors, expandability, durability of revenue, and specialty. Scale can be one of the main factors driving a dental practice’s exit multiple, because larger practices with more doctors and more durable revenue streams attract a broader pool of well-capitalized buyers and command higher multiples on a larger earnings base. Dental practice owners can often expect valuation multiples in a range of 6x to 12x EBITDA in 2026, depending on the size and health of the business.
Specialty also affects where a practice falls within that range. Oral and maxillofacial surgery often commands the highest multiples and remains one of the fastest-consolidating dental segments. Orthodontics and pediatric dentistry draw strong DSO interest and tend to earn premiums over general dentistry at comparable size. General dentistry still earns aggressive, near-all-time-high valuations, while lighter-demand specialties tend to sit at the lower end of the range. The specialty premium over general dentistry often falls in the range of one to three additional turns of EBITDA, though the specific premium for any practice depends on its individual characteristics.
Factors that can move a multiple downward within any size band include heavy Medicaid concentration, production concentrated in the selling owner, a lease with limited remaining term, and aged accounts receivable. Owner-doctor production above 50% of collections can trigger a meaningful EBITDA multiple haircut and frequently triggers a structure renegotiation with heavier earnout and multi-year post-close employment commitments.
For private-buyer deals, most general dental practices sell for 65% to 85% of annual collections, with many falling in the 70% to 85% range. This method can be useful as a screening tool for smaller practices selling to individual buyers, yet it can mislead at scale because it ignores profitability. A practice with lower collections but higher margins can be more valuable than a larger, less profitable office.
The Comparison the SERP Lacks: DSO vs. Private Buyer vs. Keeping the Practice
The comparison below highlights where the paths diverge most: cash timing, transition length, valuation method, and autonomy after close. Read it as a map of trade-offs. The DSO column tends to front-load liquidity while tying the owner to a multi-year employment term, and the private-buyer column often trades a lower headline price for a cleaner exit.
| Dimension | DSO Deal | Private-Buyer (Doctor-to-Doctor) Deal |
|---|---|---|
| Cash at Close (% of Total Consideration) | Commonly 60%–85%+ of total consideration; balance in equity and contingent payments | Purchase price commonly paid largely at close in an asset purchase; seller note sometimes used |
| Price Basis | Multiple of normalized EBITDA; scale, specialty, and durability influence the multiple | Percentage of annual collections or multiple of seller’s discretionary earnings; SBA lending often shapes affordability |
| Transition Period (Post-Close Work) | Three to five years of post-close employment typical; minimum 5-year term increasingly standard | Walk-away sale often involves roughly 4 to 8 weeks of transition; partnership or vest-out structures create a multi-year phased transition |
| Autonomy After Close | Clinical autonomy preserved in many structures but subject to management services agreement terms; operational decisions shift to the DSO | Buyer assumes full ownership and autonomy; seller exits after transition with no ongoing obligations beyond any agreed non-compete |
The third baseline, keeping the practice and taking distributions, gives owners a useful reference point. For an owner with a highly profitable practice and no immediate liquidity need, the present value of future distributions over a 10-year horizon can exceed what either a DSO or a private buyer would pay today. Many owners find value in including that comparison in the model.
Owners in the roughly $1.5 million to $3 million revenue range can often go either way, private buyer or DSO. This flexibility is one reason a side-by-side valuation across both markets can matter most for this group. The right path depends on the owner’s specific financials, goals, and timeline.
See what your practice could bring on each path with a side-by-side valuation.
How to Tell a Good DSO from a Bad One and Why Competition Changes the Terms
Because equity can make up a large share of the deal, as noted earlier, up to roughly 40%, underwriting the buyer like an investment becomes a core part of evaluating the offer. The questions worth asking include: Is the whole company profitable, or is revenue growth masking operating losses? Is same-store production growing at the offices the DSO already owns, or is growth coming entirely from new acquisitions? Is the management team experienced and stable? Has the private-equity firm backing the platform completed this kind of deal successfully before? Have the dentists who sold to them been satisfied with the post-close environment? Debt-to-EBITDA above 6x is a warning sign because the platform has limited cushion against weaker patient volume or higher interest rates, which increases equity risk for common equity holders.
The structure of the equity matters as much as the DSO’s financial health. A structural red flag in DSO deals appears when the seller is told the equity sits in a subsidiary or regional entity instead of the platform’s operating holding company, because that structure can cap upside while leaving similar downside exposure.
Running a competitive process can change the terms in a measurable way. A structured, auction-like bid process among a vetted pool of well-qualified buyers creates the competitive tension that pushes price and terms upward. The process typically runs 45 to 60 days and generates approximately 10 offers. Many dental owners who accept the first unsolicited DSO offer later learn that a real competitive process could have paid them 20% to 40% more. Without that competition, the owner negotiates alone against a counterparty who does this every week.
McLerran & Associates is a dental-only, sell-side advisory firm that represents the seller rather than the buyer. With roughly 2,000 successful practice sales, approximately $2 billion in closed transaction volume, and more than 10,000 practices evaluated, the firm runs both the DSO/private-equity path and the doctor-to-doctor private-buyer path in roughly equal measure. That dual-path capability supports a genuine side-by-side valuation rather than a recommendation shaped by a single lane. McLerran vets buyers and has blacklisted DSOs known for poor post-close environments, so weaker buyers do not reach the table. The firm’s CPA-led, diligence-grade EBITDA analysis holds up under buyer scrutiny, which reduces the risk of deals being re-traded.
Frequently Asked Questions
How Much Is a Dental Practice Worth to a DSO?
What a DSO will pay for a dental practice depends on the practice’s normalized EBITDA, its size, the number of doctors, the specialty, payer mix, and how well the practice fits the DSO’s acquisition strategy. DSOs price acquisitions on a multiple of EBITDA rather than a percentage of collections, so two practices with identical revenue but different profitability can receive very different offers. Practices with higher EBITDA, multiple providers, low owner-dependence, and strong hygiene retention tend to attract more competitive bids and higher multiples. Running a competitive process among multiple well-qualified buyers and comparing the resulting offers against a private-buyer valuation and the baseline of keeping the practice can provide the clearest picture of value.
How Many Times EBITDA Is a Dental Practice Worth?
EBITDA multiples in dental DSO transactions vary considerably based on practice size, specialty, number of providers, revenue durability, and whether the practice is an add-on to an existing platform or a potential platform acquisition in its own right. Smaller, single-location practices with lower EBITDA tend to attract lower multiples, while larger, multi-location, multi-doctor practices with higher EBITDA often attract higher multiples from a broader pool of buyers. Specialty also affects the range, with oral surgery, orthodontics, and pediatric dentistry often commanding premiums over general dentistry at comparable size. No fixed multiple applies universally. The multiple a specific practice can achieve is shaped by its individual characteristics and by how many qualified buyers are competing for it.
What Is the Typical Rule of Thumb for Valuing a Dental Practice?
The traditional rule of thumb for doctor-to-doctor private sales is a percentage of annual collections, commonly cited in the range of 65% to 85% for general dentistry, with the specific percentage influenced by profitability, patient retention, payer mix, and owner-dependence. This method can be useful as a screening tool for smaller practices selling to individual buyers, yet it can mislead at scale because it ignores profitability entirely. As the valuation section noted, collections alone can mislead, and profitability is what tends to drive value. For practices large enough to attract DSO or private-equity interest, the relevant valuation method usually shifts to a multiple of normalized EBITDA, which accounts for profitability and can produce a materially different number for well-run practices.
How Do You Sell a Dental Practice to a DSO?
Selling a dental practice to a DSO usually involves several stages. Owners build a diligence-grade EBITDA analysis and practice valuation, prepare a marketing package and virtual data room, run a competitive bid process among vetted DSO and private-equity buyers, evaluate and compare offers across their full structure, negotiate the letter of intent, and then manage due diligence through to closing. The DSO acquisition and closing process typically takes about 3 to 6 months, and the full timeline from first DSO conversation to wire transfer commonly runs 6 to 9 months. Many owners find that the most important decision is whether to approach a single DSO directly or to run a structured process that generates multiple offers and allows them to negotiate from strength. Working with a dental-specific sell-side advisor who has relationships across the buyer universe and can defend the EBITDA analysis through due diligence can be one of the main factors associated with achieving a strong outcome.
Should I Sell My Dental Practice to a DSO or Keep It?
The answer depends on the owner’s specific financial situation, goals, and timeline, and on what the numbers show across all three paths: DSO sale, private-buyer sale, and keeping the practice. A DSO affiliation can deliver a higher headline number and meaningful administrative relief, yet it comes with a multi-year work-back commitment, reduced autonomy, and equity risk that benefits from careful review. Keeping the practice and taking distributions may outperform a DSO sale over a long horizon for a highly profitable practice with a motivated owner. A private-buyer sale may fit an owner who wants a clean exit and a shorter transition. Modeling all three paths side by side, with a valuation across both the private-buyer and DSO markets and multi-year cash-flow projections that account for taxes, equity risk, and the time value of money, can provide the clearest basis for a decision.
Conclusion: A Practical Framework and Next Steps
A DSO offer functions as a financial instrument with three components, cash at close, rollover equity, and earnout, and each one behaves differently over time and after tax. Evaluating it benefits from reading those terms carefully, comparing the DSO path against a private-buyer sale and against keeping the practice, and assessing the DSO’s financial backing before signing anything. The headline multiple is only the starting point. The earnings base it is applied to, the structure of the equity, the earnout mechanics, and the post-close employment terms all influence what the owner ultimately receives.
Next steps can be straightforward. Owners can review their financials with a dental-specific advisor, clarify goals and timeline, compare transition paths with a side-by-side valuation, and speak with an advisor who runs both paths and can show the numbers before any commitment.
McLerran & Associates is one of the firms working both the DSO/private-equity path and the doctor-to-doctor private-buyer path in roughly equal measure, approximately 50/50, which gives clients a genuine side-by-side comparison that single-lane brokers may not provide. The firm’s CPA-led, diligence-grade EBITDA analysis is designed to hold up under buyer scrutiny, and its structured, auction-like process among a vetted pool of well-qualified buyers typically generates around 10 offers per listing.
Review your options with a confidential call to McLerran & Associates.
Reserve your spot at the McLerran M&A Summit (October 29–30, 2026) for undecided owners.
